|4.||Sickle Cell Anemia (Hemoglobin S Disease)
|5.||Human Influenza (Influenza)
|1.||Briles, David E: 17 articles (07/2014 - 04/2002)|
|2.||Yin, Yibing: 13 articles (02/2015 - 06/2007)|
|3.||Zhang, Xuemei: 12 articles (02/2015 - 06/2007)|
|4.||Cao, Ju: 9 articles (01/2014 - 06/2007)|
|5.||Hammerschmidt, Sven: 8 articles (12/2015 - 07/2004)|
|6.||Briles, D E: 8 articles (09/2015 - 01/2000)|
|7.||Paton, James C: 8 articles (06/2015 - 12/2002)|
|8.||Kadioglu, Aras: 8 articles (05/2015 - 05/2004)|
|9.||Xu, Wenchun: 8 articles (02/2015 - 06/2007)|
|10.||Wang, Hong: 8 articles (02/2015 - 03/2010)|
01/01/2014 - "In patients (89%-100%), antibodies against most serotypes reached trough levels ≥ 0.2 µg/mL, a threshold considered protective against invasive pneumococcal infection. "
04/30/2001 - "Thus, high avidity of serum antibodies in conjugate-immunized mice can provide more effective functional activity for protection against pneumococcal infection. "
08/31/2001 - "The N-terminal, cell surface exposed, and functional part of PspA is essential for full pneumococcal virulence, as evidenced by the fact that antibodies raised against this part of the protein are protective against pneumococcal infections. "
10/01/2006 - "These results suggest that antibodies to PotD confer protection against invasive pneumococcal disease and that this protein should be studied further as a potential vaccine candidate for protection against invasive pneumococcal infections."
02/01/2010 - "To assess whether the production of mucosal and systemic antibodies was able to afford protection against respiratory pneumococcal infection, challenge experiments with the pathogenic serotypes 3, 6B, 14, and 23F were carried out. "
|2.||Penicillins (Penicillin)FDA Link
04/01/2014 - "Results of the two included randomized controlled trials showed a significant reduction in the incidence of pneumococcal infection among children with SCA (and (0)-thallasaemia) receiving penicillin compared to the control group treated with placebo. "
03/01/2004 - "The efficacy of oral penicillin prophylaxis against pneumococcal infections has been well demonstrated and is now recommended from 3 months of age. "
05/26/1984 - "The efficacy of prophylactic penicillin and of 14 valent pneumococcal vaccine in preventing pneumococcal infection in homozygous sickle cell (SS) disease was investigated in 242 children aged 6 months to 3 years at entry. "
04/01/2014 - "Randomized controlled trials comparing oral penicillin prophylaxis for the prevention of pneumococcal infection in children with SCA with placebo or no treatment were searched for. "
01/01/2014 - "In trials which investigated initiation of penicillin on risk of pneumococcal infection, the odds ratio was 0.37 (95% CI 0.16 to 0.86), while for withdrawal the odds ratio was 0.49 (95% CI 0.09 to 2.71). "
12/01/1998 - "Preventing pneumococcal infections with safe and effective vaccines will not only reduce the development of antibiotic resistance, but could also be the most cost-effective method to control pneumococcal disease."
03/01/1998 - "Pneumococcal polysaccharide vaccines are not protective against the most common pneumococcal infections in infancy. "
01/01/2004 - "Pneumococcal vaccination with the currently available polysaccharide vaccine is thought to confer some preventive benefit (preventing invasive pneumococcal disease), but more effective vaccines, such as nonconjugate protein vaccines, need to be developed that provide broad protection against pneumococcal infection."
01/01/2014 - "Vaccines have long been used for protection against pneumococcal infections. "
01/01/2014 - "The efficacy of different vaccines in protecting elderly individuals against Streptococcus pneumoniae infections is not clear. "
|4.||Anti-Bacterial Agents (Antibiotics)IBA
04/01/2005 - "Antibiotics have to be effective against pneumococcal infection. "
12/01/2003 - "Grouping the 1,738 analyzable patients in these four studies, a meta-analysis was performed on the sub-group of 275 patients with documented pneumococcal infection (86 with bacteriemia) in order to compare the efficacy of levofloxacine with that of the comparer antibiotics. "
03/01/2006 - "The results obtained in this study will allow to orient the empiric therapy for pneumococcal infections and a rational use of antibiotics in clinical practice, as well as the application of an appropriate vaccination program specially adapted to the serotypes more frequently found in children."
06/19/2015 - "Pneumococcal infections can be treated with β-lactam antibiotics, but rapid emergence of multidrug-resistant strains of S. "
04/01/2015 - "Antibiotics are mandatory; they should be initiated as quickly as possible and should be active against anaerobic bacteria except for in the context of pneumococcal infections. "
11/01/2008 - "MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen."
11/01/2014 - "This study confirmed that the ICT urinary antigen test remained to have a high sensitivity for diagnosis of pneumococcal infection after empiric antibiotic treatment was started. "
06/01/2006 - "The aim of the study was to evaluate the Binax Now rapid immunochromatographic test (ICT) for the detection of Streptococcus pneumoniae urinary antigen in children suffering from potentially pneumococcal infections. "
06/30/1940 - "STUDIES ON ANTIBACTERIAL IMMUNITY INDUCED BY ARTIFICIAL ANTIGENS : II. IMMUNITY TO EXPERIMENTAL PNEUMOCOCCAL INFECTION WITH ANTIGENS CONTAINING SACCHARIDES OF SYNTHETIC ORIGIN."
02/28/1939 - "STUDIES ON ANTIBACTERIAL IMMUNITY INDUCED BY ARTIFICIAL ANTIGENS : I. IMMUNITY TO EXPERIMENTAL PNEUMOCOCCAL INFECTION WITH AN ANTIGEN CONTAINING CELLOBIURONIC ACID."
|6.||pneumococcal surface protein AIBA
01/01/2011 - "The current study was designed to evaluate the protection against fatal pneumococcal infections during the infant period by maternal immunization with pneumococcal surface protein A (PspA). "
12/01/2008 - "Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA)."
09/01/2001 - "Pneumococcal surface protein A (PspA) is a pneumococcal virulence factor capable of eliciting protection against pneumococcal infection in mice. "
12/01/2008 - "The aim of this study was to evaluate the protection conferred against fatal pneumococcal infections during infancy by maternal intranasal immunization with pneumococcal surface protein A (PspA). "
11/01/2012 - "Pneumococcal surface protein A (PspA) is an important candidate for a vaccine against pneumococcal infections. "
10/01/2012 - "pneumoniae with new conjugate vaccines seems to be the most promising field for real improvement in the management of pneumococcal infections in adults."
03/20/2002 - "Finally, the introduction of pneumococcal conjugate vaccines, which are highly efficacious in infants and young children, will provide the opportunity for successful prevention of vaccine-type invasive pneumococcal infections."
04/01/2002 - "Pneumococcal conjugate vaccines are intended to provide effective protection against pneumococcal infections, but very little information on antibody responses in infants living in countries with high pneumococcal disease burden exists. "
08/01/2006 - "The vaccine is effective against invasive and non-invasive pneumococcal infection, can be used in young children as well as adults and, like all conjugate vaccines, provides long-lasting immunity. "
01/01/2013 - "The protection against pneumococcal infections provided by currently available pneumococcal polysaccharide conjugate vaccines are restricted to the limited number of the serotypes included in the vaccine. "
|8.||Proteins (Proteins, Gene)IBA
04/01/2014 - "DnaJ has been approved as a useful candidate vaccine protein; we therefore designed novel fusion proteins of DnaJ with a form of Ply that has a deletion of A146 (ΔA146Ply-DnaJ [the C terminus of ΔA146Ply connected with the N terminus of DnaJ] and DnaJ-ΔA146Ply [the C terminus of DnaJ connected with the N terminus of ΔA146Ply]) to test whether they are protective against focal and lethal pneumococcal infections and their potential protective mechanisms. "
02/25/2000 - "The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection."
06/27/2012 - "When the optimized conditions were applied to several clinical isolates, we found the majority of the proteins described to induce protection against pneumococcal infection. "
03/01/2010 - "Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice."
01/01/2013 - "The present study investigated the potential of hybrid proteins generated by genetic fusion of PspA fragments to Pds to increase cross-protection against fatal pneumococcal infection. "
|9.||Streptococcus pneumoniae plY proteinIBA
03/01/2001 - "This study examined the hypothesis that human antibody to pneumolysin provides protection against pneumococcal infection. "
03/01/2001 - "Protection against bacteremic pneumococcal infection by antibody to pneumolysin."
05/01/2015 - "Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection."
07/15/2014 - "We found that primary human monocyte-derived macrophages as well as THP-1 macrophages produced MIF upon pneumococcal infection in a pneumolysin-dependent manner. "
09/01/2011 - "Stimulation of CCL2 by macrophages upon pneumococcal infection alone required the pattern recognition receptor Nod2 and expression of the pore-forming toxin pneumolysin. "
|10.||Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA
05/01/1985 - "The commercial availability of a 14-valent pneumococcal polysaccharide vaccine justifies repeated investigations of the prevalent pneumococcal serotypes to estimate the probable efficacy of vaccination for patients at high risk of pneumococcal infection. "
07/30/1999 - "Because these new generation pneumococcal vaccines could provide a foundation of life-long protection against pneumococcal infection, their widespread use among adults could have an immense impact on public health worldwide."
11/01/2015 - "Effectiveness appraisal of current anti-pneumococcal vaccines and the perspectives in terms of preventive strategies against Streptococcus pneumoniae infections in the adult population are presented. "
01/01/2015 - "Pneumococcal vaccines licensed did not reach to eradicate the pneumococcal infection. "
06/01/2014 - "Global control of pneumococcal infections by pneumococcal vaccines."
11/01/1977 - "The observation that a limited number of pneumococcal serotypes, particularly type XII, appear to predominate in these cases suggests that pneumococcal vaccine might be highly efficacious in preventing overwhelming post-splenectomy pneumococcal infections in otherwise-normal hosts."
07/01/1988 - "Patients undergoing greater than 50% splenectomy may be afforded greater protection against overwhelming pneumococcal infections by immunization with pneumococcal vaccine."
07/01/2008 - "We analysed routinely collected, linked statistical records of hospital admission to study the risk of pneumococcal infection in patients with coeliac disease, in patients who underwent splenectomy and in a comparison cohort. "
02/01/1991 - "Due to the similarity of the porcine immune system to man we chose the pig to study subsets of peripheral mononuclear cells after splenectomy and resistance to experimental Pneumococcal infection after splenic surgery and specific immunization. "
01/01/2012 - "In general, splenectomy is known as a risk factor of pneumococcal infection. "
12/01/1984 - "Effect of exchange transfusion with an oxygen-carrying resuscitation fluid on the efficacy of penicillin therapy of pneumococcal infection in rats."
02/01/1987 - "Exchange transfusion with the oxygen-carrying resuscitation fluid, Fluosol DA 20% (FDA), interferes with the efficacy of penicillin therapy of pneumococcal infection in rats. "
01/01/2012 - "This study provides exciting new evidence for the importance of immunomodulation during pulmonary pneumococcal infection and suggests that TGF-β signalling is a potential target for immunotherapy or drug design."
04/01/2007 - "Taken together, our data extend the association between antibody-mediated protection and immunomodulation to protection against systemic pneumococcal infection and to a clinically important serotype often responsible for pneumococcal sepsis."
09/01/2010 - "Early diagnosis of Hib and pneumococcal infections combined with antibiotic prophylaxis and immunization programs, could lead to significant improvements in mortality, especially in Africa."
09/06/2003 - "Current guidelines concerning antibiotic prophylaxis in asplenic and hyposplenic children are based on several notions: not giving antibiotic prophylaxis is unacceptable due to the major vulnerability of these children to pneumococcal infection and the frequence of pneumococcal colonization in this age group; the antibiotic given should have a narrow spectrum. "
06/01/2002 - "Although the possible mechanisms of rhabodomyolysis associated with pneumococcal infection remain unclear, this report may serve to alert clinicians of the need to prevent fulminant pneumococcal infection by vaccination and treatment with antibiotic prophylaxis in splenectomized patients."
12/01/2004 - "Early recognition and therapy of hypocalcemia is important as is daily antibiotic prophylaxis against pneumococcal infections."
08/27/2003 - "Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics."
10/01/2008 - "To our knowledge, this is the first demonstration of protection against respiratory pneumococcal infection induced by oral administration of a recombinant lactococcal vaccine."
01/01/1993 - "vulgaris, the effectiveness index was 2.7 (immunization was made in two oral administrations of 2 mg); in pneumococcal infection preliminary oral immunization with vaccine VP-4 in two administrations in a dose of 2-4 mg produced high protective effect. "